A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with Other Anti-cancer Agents in Patients with Metastatic HER2-low Breast Cancer (DESTINY-Breast08) - D967JC00002

Astrazeneca AB0 个研究点目标入组 192 人开始时间: 2024年7月15日最近更新: 2024年8月21日

适应症

试验速览

暂无简介。

•Patients must be at least 18 years of age, Male or female patients who have pathologically documented breast cancer that: a)Has a history of HER2-low expression, defined as IHC 2+/ISH- or IHC 1+ (ISH- or untested) with a validated assay b)Is documented as HR+ (either ER and/or PgR positive [ER or PgR = 1%]) or ER and PgR negative (ER and PgR <1%) per ASCO/CAP guidelines in the metastatic setting, Patient must have adequate tumor sample for biomarker assessment, ECOG Performance Status of 0 or 1, For patients with HR+ disease: Part 1: At least 1 prior treatment line of ET with or without a targeted therapy (such as CDK4/6, mTOR or PI3-K inhibitors), and at least 1 prior line of chemotherapy for MBC are required. Part 2: Only 1 prior treatment line of ET with or without a targeted therapy (such as CDK4/6, mTOR or PI3-K inhibitors) for MBC is allowed. No prior chemotherapy in the metastatic setting is allowed. Note there are no patients with HR+ disease in Part 2 of Modules 2 and 3., For patients with HR- disease: Part 1: At least 1 prior line of chemotherapy for MBC is required. Note there are no patients with HR- disease in Part 1 of Modules 4 and 5. Part 2: For Module 2, no prior lines of therapy for MBC are allowed, and for Modules 1 and 3, only 1 prior line of chemotherapy for MBC is allowed. Note there are no patients with HR- disease in Part 2 of Modules 4 and 5.

•Uncontrolled intercurrent illness, Uncontrolled or significant cardiovascular disease, History of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening, Lung-specific intercurrent clinically significant illnesses, Has spinal cord compression or clinically active central nervous system metastases, Active primary immunodeficiency, Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals, Prior treatment with ADC that comprises of an exatecan derivative that is a topoisomerase I inhibitor, Combination partner as the most recent anti-cancer therapy for MBC prior to commencing study treatment

发起方